Analysis on orphan drug security policy from the perspective of drug life cycle in ChinaYUAN Ni, ZHOU Na, ZHANG Hai-jun, LI Zheng, ZHANG Xu, WANG Yong1-5
Relationship between regional level of pharmaceutical economic development and R&D capital investment in pharmaceutical manufacturing industry in ChinaLI Wan-ting, WANG Su, CHEN Yu-wen6-12
Key points on direct distribution for national drug reference standardsGAO Zhi-feng, XIAO Xin-yue, CAO Li-mei, XIE Li-hua, JIANG Jing-yu, SHAO Jun-juan13-16
Development of background data on repeated toxicity studies in juvenile SD ratsCHONG Li-ming, YANG Yang, CHEN Li-fen, XU Li, CHEN Ding-shi, WANG Zhong-hui, ZHOU Li, SUN Zu-yue17-24
Development and validation of a cell-based reporter gene assay for bioactivity determination of anti-EpCAM+CD3 bispecific antibodyZHANG Hong-mei, ZHANG Feng, LIU Chun-yu, YU Chuan-fei, DUAN Mao-qin, CAO Jun-xia, HUANG Jing, WANG Kai-qin, GUO Xiao, WANG Lan25-34
Countermeasures for drug clinical trial management under major public health emergenciesPENG Peng, YUAN Wei-an, HU Yi-hui, TANG Jie35-37
Research progress of immune checkpoint inhibitor-induced acute kidney injuryWANG Long, JIN Rong, HAN Yi-xuan, WANG Juan, ZHU Ling-na38-42
Determination of dexrabeprazole and levrabeprazole in human plasma by HPLC-MS/MS and its pharmacokinetic studyLI Xiang-hong, XIE Hai-tang, LIANG Da-hu, SUN Hua, ZHOU Li-xiang, DAI Min, YANG Bin, WANG Wei-jia, SHEN Jie, ZHAO Ya-nan43-49
Investigation and research on the state of clinical trials during epidemic period of COVID-19ZHU Xiao-fang, DAI Jian, LIU Ling-ye, ZHU Jing-jing, LU Meng, WANG Lu-lu, ZHU Qing, WANG Jian50-54
Ameliorative effect and mechanism of mosloflavone on hypobaric hypoxia-induced heart damage in miceLIU Rui, SHAO Jin, ZHAO Tong, MA Hui-ping, HE Lei, JING Lin-lin55-61